Osteoporosis - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：256頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Osteoporosis - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2014’, provides an overview of the Osteoporosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoporosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Osteoporosis - Pipeline Review, H1 2014’, provides an overview of the Osteoporosis’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoporosis and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Osteoporosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Osteoporosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Osteoporosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Osteoporosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Osteoporosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Osteoporosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoporosis Overview 10
Therapeutics Development 11
Pipeline Products for Osteoporosis - Overview 11
Pipeline Products for Osteoporosis - Comparative Analysis 12
Osteoporosis - Therapeutics under Development by Companies 13
Osteoporosis - Therapeutics under Investigation by Universities/Institutes 19
Osteoporosis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Osteoporosis - Products under Development by Companies 25
Osteoporosis - Products under Investigation by Universities/Institutes 30
Osteoporosis - Companies Involved in Therapeutics Development 31
F. Hoffmann-La Roche Ltd. 31
Amgen Inc. 32
Eli Lilly and Company 33
Daiichi Sankyo Company, Limited 34
Merck & Co., Inc. 35
Dainippon Sumitomo Pharma Co., Ltd. 36
Takeda Pharmaceutical Company Limited 37
CardioVascular BioTherapeutics, Inc. 38
Glide Pharmaceutical Technologies Limited 39
Novartis AG 40
Astellas Pharma Inc. 41
Chugai Pharmaceutical Co., Ltd. 42
Pfizer Inc. 43
Zydus Cadila Healthcare Limited 44
Azelon Pharmaceuticals Inc. 45
Biodel Inc. 46
Zosano Pharma, Inc. 47
Bone Medical Limited 48
FAES Farma SA 49
Enzo Biochem, Inc. 50
Kaken Pharmaceutical Co., Ltd. 51
Lupin Limited 52
Medivir AB 53
Calzada Limited 54
NeoStem, Inc. 55
Dongwha Pharm Co., Ltd. 56
PhytoHealth Corporation 57
Galapagos NV 58
Uni-Bio Science Group Ltd. 59
Oscotec Inc. 60
Dongkook Pharmaceutical Co., Ltd. 61
Merrion Pharmaceuticals Plc 62
Deltanoid Pharmaceuticals Inc. 63
Ventria Bioscience 64
Critical Pharmaceuticals Limited 65
Alkem Laboratories Ltd. 66
Amura Holdings Ltd. 67
Affectis Pharmaceuticals AG 68
IMMD Inc. 69
Alethia Biotherapeutics Inc. 70
Kedem Pharmaceuticals Inc. 71
Asahi Kasei Pharma Corp. 72
Pantarhei Bioscience BV 73
Zealand Pharma A/S 74
Siena Biotech S.p.A. 75
Radius Health, Inc. 76
Ensoltek Co., Ltd. 77
Pradama, Inc. 78
B&C Biopharm 79
TSRL, Inc. 80
Pfenex Inc. 81
Ausio Pharmaceuticals, LLC 82
Shenogen Pharma Group Ltd. 83
Biolo ElexoPharm GmbH 84
Inbiopro Solutions Pvt. Ltd. 85
Bone Therapeutics SA 86
Wroclawskie Centrum Badan EIT+ Sp. z o.o. 87
Centre de Regulacio Genomica 88
Covigilance sro 89
Amgen Astellas BioPharma K.K. 90
Osteoporosis - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Target 93
Assessment by Mechanism of Action 97
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 106
bazedoxifene acetate - Drug Profile 106
denosumab - Drug Profile 107
romosozumab - Drug Profile 110
odanacatib - Drug Profile 112
BA-058 - Drug Profile 114
zoledronic acid - Drug Profile 117
ibandronate sodium - Drug Profile 119
estrone sodium sulfate + (levonorgestrel + Ethinyl Estradiol) + prasterone - Drug Profile 121
teriparatide - Drug Profile 122
COVOP-77 - Drug Profile 123
E-4 - Drug Profile 124
teriparatide - Drug Profile 126
calcitonin - Drug Profile 127
PHN-031 - Drug Profile 129
teriparatide - Drug Profile 130
teriparatide ZP Patch - Drug Profile 132
alendronate sodium - Drug Profile 134
DP-001 - Drug Profile 136
blosozumab - Drug Profile 138
ES-1 - Drug Profile 139
PREOB - Drug Profile 140
AUS-131 - Drug Profile 141
IMD-2560 - Drug Profile 143
MIV-711 - Drug Profile 144
DW-1350 - Drug Profile 145
ZYPH-0907 - Drug Profile 146
OCT-1547 - Drug Profile 147
teriparatide - Drug Profile 148
CDRI-99/373 - Drug Profile 149
VEN-130 - Drug Profile 150
Oratonin - Drug Profile 151
teriparatide acetate transdermal patch - Drug Profile 152
teriparatide - Drug Profile 153
Recombinant salmon calcitonin - Drug Profile 154
Osteoblasts for Osteoporosis and Bone Fractures - Drug Profile 155
CVBT-141G - Drug Profile 156
AOD-9604 - Drug Profile 157
ZP-2307 - Drug Profile 159
MIV-710 - Drug Profile 160
Small Molecule To Modulate LRP For Osteoporosis - Drug Profile 161
AB-25E9 - Drug Profile 162
AM-3701 - Drug Profile 163
BN-005 - Drug Profile 164
BN-008 - Drug Profile 165
BC-6213 - Drug Profile 166
RAD-140 - Drug Profile 167
Sodium Quinate - Drug Profile 168
Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile 169
PTH-CBD - Drug Profile 170
ARC-205 - Drug Profile 171
Drug For Osteoporosis - Drug Profile 172
denosumab biosimilar - Drug Profile 173
TSG-6 - Drug Profile 174
S-101479 - Drug Profile 175
Calcitonin Receptor Peptide - Drug Profile 176
Small Molecule to Inhibit 17Beta-HSD2 for Osteoporosis and Bone Fracture - Drug Profile 177
IPS-02001 - Drug Profile 178
CH-5036249 - Drug Profile 179
alendronate sodium - Drug Profile 180
Astrogorgiadiol - Drug Profile 181
teriparatide biosimilar - Drug Profile 182
Compound-99-373 - Drug Profile 183
S-007-1500 - Drug Profile 184
Eu-232 - Drug Profile 185
AS-2690168 - Drug Profile 186
NEP-28 - Drug Profile 187
Tetrahydroquinoline Derivative - Drug Profile 188
Biosimilar for Osteoporosis - Drug Profile 189
TAK-075 - Drug Profile 190
Antibody Program For Bone Disorders - Drug Profile 191
Osteoporosis Program - Drug Profile 192
Antiosteoporotic - Drug Profile 193
AFC-5278 - Drug Profile 194
ODS-656 - Drug Profile 195
Monoclonal Antibody For Bone Diseases - Drug Profile 196
Gene Re-Combination Proteins - Drug Profile 197
UBS-109 - Drug Profile 198
teriparatide - Drug Profile 199
VS-401 - Drug Profile 200
Vida-411 - Drug Profile 201
enoxacin - Drug Profile 202
SNG-8006 - Drug Profile 203
Peniel-3000 - Drug Profile 204
Small Molecules to Inhibit Src Tyrosine Kinases for Cardiovascular Disorders, Oncology and Osteoporosis - Drug Profile 205
Anti-Osteoporosis Drugs - Drug Profile 206
Isoxazoles - Drug Profile 207
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 208
RANKL Inhibitory Proteins - Drug Profile 209
Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drug Profile 210
Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Drug Profile 211
Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders - Drug Profile 212
teriparatide ZP Patch - Drug Profile 213
IBPB-008-IG - Drug Profile 215
KDM-1103 - Drug Profile 216
Osteoporosis - Recent Pipeline Updates 217
Osteoporosis - Dormant Projects 236
Osteoporosis - Discontinued Products 240
Osteoporosis - Product Development Milestones 241
Featured News & Press Releases 241
Appendix 248
Methodology 248
Coverage 248
Secondary Research 248
Primary Research 248
Expert Panel Validation 248
Contact Us 249
Disclaimer 249
List of Tables
Number of Products under Development for Osteoporosis, H1 2014 18
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Development by Companies, H1 2014 (Contd..1) 33
Products under Development by Companies, H1 2014 (Contd..2) 34
Products under Development by Companies, H1 2014 (Contd..3) 35
Products under Development by Companies, H1 2014 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2014 37
Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 38
Osteoporosis - Pipeline by Amgen Inc., H1 2014 39
Osteoporosis - Pipeline by Eli Lilly and Company, H1 2014 40
Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 41
Osteoporosis - Pipeline by Merck & Co., Inc., H1 2014 42
Osteoporosis - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 43
Osteoporosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 44
Osteoporosis - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 45
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2014 46
Osteoporosis - Pipeline by Novartis AG, H1 2014 47
Osteoporosis - Pipeline by Astellas Pharma Inc., H1 2014 48
Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 49
Osteoporosis - Pipeline by Pfizer Inc., H1 2014 50
Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 51
Osteoporosis - Pipeline by Azelon Pharmaceuticals Inc., H1 2014 52
Osteoporosis - Pipeline by Biodel Inc., H1 2014 53
Osteoporosis - Pipeline by Zosano Pharma, Inc., H1 2014 54
Osteoporosis - Pipeline by Bone Medical Limited, H1 2014 55
Osteoporosis - Pipeline by FAES Farma SA, H1 2014 56
Osteoporosis - Pipeline by Enzo Biochem, Inc., H1 2014 57
Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2014 58
Osteoporosis - Pipeline by Lupin Limited, H1 2014 59
Osteoporosis - Pipeline by Medivir AB, H1 2014 60
Osteoporosis - Pipeline by Calzada Limited, H1 2014 61
Osteoporosis - Pipeline by NeoStem, Inc., H1 2014 62
Osteoporosis - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 63
Osteoporosis - Pipeline by PhytoHealth Corporation, H1 2014 64
Osteoporosis - Pipeline by Galapagos NV, H1 2014 65
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H1 2014 66
Osteoporosis - Pipeline by Oscotec Inc., H1 2014 67
Osteoporosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 68
Osteoporosis - Pipeline by Merrion Pharmaceuticals Plc, H1 2014 69
Osteoporosis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2014 70
Osteoporosis - Pipeline by Ventria Bioscience, H1 2014 71
Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H1 2014 72
Osteoporosis - Pipeline by Alkem Laboratories Ltd., H1 2014 73
Osteoporosis - Pipeline by Amura Holdings Ltd., H1 2014 74
Osteoporosis - Pipeline by Affectis Pharmaceuticals AG, H1 2014 75
Osteoporosis - Pipeline by IMMD Inc., H1 2014 76
Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H1 2014 77
Osteoporosis - Pipeline by Kedem Pharmaceuticals Inc., H1 2014 78
Osteoporosis - Pipeline by Asahi Kasei Pharma Corp., H1 2014 79
Osteoporosis - Pipeline by Pantarhei Bioscience BV, H1 2014 80
Osteoporosis - Pipeline by Zealand Pharma A/S, H1 2014 81
Osteoporosis - Pipeline by Siena Biotech S.p.A., H1 2014 82
Osteoporosis - Pipeline by Radius Health, Inc., H1 2014 83
Osteoporosis - Pipeline by Ensoltek Co., Ltd., H1 2014 84
Osteoporosis - Pipeline by Pradama, Inc., H1 2014 85
Osteoporosis - Pipeline by B&C Biopharm, H1 2014 86
Osteoporosis - Pipeline by TSRL, Inc., H1 2014 87
Osteoporosis - Pipeline by Pfenex Inc., H1 2014 88
Osteoporosis - Pipeline by Ausio Pharmaceuticals, LLC, H1 2014 89
Osteoporosis - Pipeline by Shenogen Pharma Group Ltd., H1 2014 90
Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2014 91
Osteoporosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 92
Osteoporosis - Pipeline by Bone Therapeutics SA , H1 2014 93
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2014 94
Osteoporosis - Pipeline by Centre de Regulacio Genomica, H1 2014 95
Osteoporosis - Pipeline by Covigilance sro, H1 2014 96
Osteoporosis - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 97
Assessment by Monotherapy Products, H1 2014 98
Assessment by Combination Products, H1 2014 99
Number of Products by Stage and Target, H1 2014 102
Number of Products by Stage and Mechanism of Action, H1 2014 106
Number of Products by Stage and Route of Administration, H1 2014 109
Number of Products by Stage and Molecule Type, H1 2014 112
Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2014 224
Osteoporosis - Dormant Projects, H1 2014 243
Osteoporosis - Dormant Projects (Contd..1), H1 2014 244
Osteoporosis - Dormant Projects (Contd..2), H1 2014 245
Osteoporosis - Dormant Projects (Contd..3), H1 2014 246
Osteoporosis - Discontinued Products, H1 2014 247
List of Figures
Number of Products under Development for Osteoporosis, H1 2014 18
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 98
Number of Products by Top 10 Target, H1 2014 100
Number of Products by Stage and Top 10 Target, H1 2014 101
Number of Products by Top 10 Mechanism of Action, H1 2014 104
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 105
Number of Products by Top 10 Route of Administration, H1 2014 108
Number of Products by Stage and Top 10 Route of Administration, H1 2014 109
Number of Products by Top 10 Molecule Type, H1 2014 110
Number of Products by Stage and Top 10 Molecule Type, H1 2014 111
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Osteoporosis Overview 10
Therapeutics Development 11
Pipeline Products for Osteoporosis - Overview 11
Pipeline Products for Osteoporosis - Comparative Analysis 12
Osteoporosis - Therapeutics under Development by Companies 13
Osteoporosis - Therapeutics under Investigation by Universities/Institutes 19
Osteoporosis - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Osteoporosis - Products under Development by Companies 25
Osteoporosis - Products under Investigation by Universities/Institutes 30
Osteoporosis - Companies Involved in Therapeutics Development 31
F. Hoffmann-La Roche Ltd. 31
Amgen Inc. 32
Eli Lilly and Company 33
Daiichi Sankyo Company, Limited 34
Merck & Co., Inc. 35
Dainippon Sumitomo Pharma Co., Ltd. 36
Takeda Pharmaceutical Company Limited 37
CardioVascular BioTherapeutics, Inc. 38
Glide Pharmaceutical Technologies Limited 39
Novartis AG 40
Astellas Pharma Inc. 41
Chugai Pharmaceutical Co., Ltd. 42
Pfizer Inc. 43
Zydus Cadila Healthcare Limited 44
Azelon Pharmaceuticals Inc. 45
Biodel Inc. 46
Zosano Pharma, Inc. 47
Bone Medical Limited 48
FAES Farma SA 49
Enzo Biochem, Inc. 50
Kaken Pharmaceutical Co., Ltd. 51
Lupin Limited 52
Medivir AB 53
Calzada Limited 54
NeoStem, Inc. 55
Dongwha Pharm Co., Ltd. 56
PhytoHealth Corporation 57
Galapagos NV 58
Uni-Bio Science Group Ltd. 59
Oscotec Inc. 60
Dongkook Pharmaceutical Co., Ltd. 61
Merrion Pharmaceuticals Plc 62
Deltanoid Pharmaceuticals Inc. 63
Ventria Bioscience 64
Critical Pharmaceuticals Limited 65
Alkem Laboratories Ltd. 66
Amura Holdings Ltd. 67
Affectis Pharmaceuticals AG 68
IMMD Inc. 69
Alethia Biotherapeutics Inc. 70
Kedem Pharmaceuticals Inc. 71
Asahi Kasei Pharma Corp. 72
Pantarhei Bioscience BV 73
Zealand Pharma A/S 74
Siena Biotech S.p.A. 75
Radius Health, Inc. 76
Ensoltek Co., Ltd. 77
Pradama, Inc. 78
B&C Biopharm 79
TSRL, Inc. 80
Pfenex Inc. 81
Ausio Pharmaceuticals, LLC 82
Shenogen Pharma Group Ltd. 83
Biolo ElexoPharm GmbH 84
Inbiopro Solutions Pvt. Ltd. 85
Bone Therapeutics SA 86
Wroclawskie Centrum Badan EIT+ Sp. z o.o. 87
Centre de Regulacio Genomica 88
Covigilance sro 89
Amgen Astellas BioPharma K.K. 90
Osteoporosis - Therapeutics Assessment 91
Assessment by Monotherapy Products 91
Assessment by Combination Products 92
Assessment by Target 93
Assessment by Mechanism of Action 97
Assessment by Route of Administration 101
Assessment by Molecule Type 103
Drug Profiles 106
bazedoxifene acetate - Drug Profile 106
denosumab - Drug Profile 107
romosozumab - Drug Profile 110
odanacatib - Drug Profile 112
BA-058 - Drug Profile 114
zoledronic acid - Drug Profile 117
ibandronate sodium - Drug Profile 119
estrone sodium sulfate + (levonorgestrel + Ethinyl Estradiol) + prasterone - Drug Profile 121
teriparatide - Drug Profile 122
COVOP-77 - Drug Profile 123
E-4 - Drug Profile 124
teriparatide - Drug Profile 126
calcitonin - Drug Profile 127
PHN-031 - Drug Profile 129
teriparatide - Drug Profile 130
teriparatide ZP Patch - Drug Profile 132
alendronate sodium - Drug Profile 134
DP-001 - Drug Profile 136
blosozumab - Drug Profile 138
ES-1 - Drug Profile 139
PREOB - Drug Profile 140
AUS-131 - Drug Profile 141
IMD-2560 - Drug Profile 143
MIV-711 - Drug Profile 144
DW-1350 - Drug Profile 145
ZYPH-0907 - Drug Profile 146
OCT-1547 - Drug Profile 147
teriparatide - Drug Profile 148
CDRI-99/373 - Drug Profile 149
VEN-130 - Drug Profile 150
Oratonin - Drug Profile 151
teriparatide acetate transdermal patch - Drug Profile 152
teriparatide - Drug Profile 153
Recombinant salmon calcitonin - Drug Profile 154
Osteoblasts for Osteoporosis and Bone Fractures - Drug Profile 155
CVBT-141G - Drug Profile 156
AOD-9604 - Drug Profile 157
ZP-2307 - Drug Profile 159
MIV-710 - Drug Profile 160
Small Molecule To Modulate LRP For Osteoporosis - Drug Profile 161
AB-25E9 - Drug Profile 162
AM-3701 - Drug Profile 163
BN-005 - Drug Profile 164
BN-008 - Drug Profile 165
BC-6213 - Drug Profile 166
RAD-140 - Drug Profile 167
Sodium Quinate - Drug Profile 168
Stem Cell Therapy For Osteoporosis And Bone Regeneration - Drug Profile 169
PTH-CBD - Drug Profile 170
ARC-205 - Drug Profile 171
Drug For Osteoporosis - Drug Profile 172
denosumab biosimilar - Drug Profile 173
TSG-6 - Drug Profile 174
S-101479 - Drug Profile 175
Calcitonin Receptor Peptide - Drug Profile 176
Small Molecule to Inhibit 17Beta-HSD2 for Osteoporosis and Bone Fracture - Drug Profile 177
IPS-02001 - Drug Profile 178
CH-5036249 - Drug Profile 179
alendronate sodium - Drug Profile 180
Astrogorgiadiol - Drug Profile 181
teriparatide biosimilar - Drug Profile 182
Compound-99-373 - Drug Profile 183
S-007-1500 - Drug Profile 184
Eu-232 - Drug Profile 185
AS-2690168 - Drug Profile 186
NEP-28 - Drug Profile 187
Tetrahydroquinoline Derivative - Drug Profile 188
Biosimilar for Osteoporosis - Drug Profile 189
TAK-075 - Drug Profile 190
Antibody Program For Bone Disorders - Drug Profile 191
Osteoporosis Program - Drug Profile 192
Antiosteoporotic - Drug Profile 193
AFC-5278 - Drug Profile 194
ODS-656 - Drug Profile 195
Monoclonal Antibody For Bone Diseases - Drug Profile 196
Gene Re-Combination Proteins - Drug Profile 197
UBS-109 - Drug Profile 198
teriparatide - Drug Profile 199
VS-401 - Drug Profile 200
Vida-411 - Drug Profile 201
enoxacin - Drug Profile 202
SNG-8006 - Drug Profile 203
Peniel-3000 - Drug Profile 204
Small Molecules to Inhibit Src Tyrosine Kinases for Cardiovascular Disorders, Oncology and Osteoporosis - Drug Profile 205
Anti-Osteoporosis Drugs - Drug Profile 206
Isoxazoles - Drug Profile 207
Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Musculoskeletal Disorders - Drug Profile 208
RANKL Inhibitory Proteins - Drug Profile 209
Epoxyeicosatreienoic Acid Analogues for Musculoskeletal Disorders - Drug Profile 210
Drugs to Modulate PPAR-Delta for Musculoskeletal Disorders - Drug Profile 211
Hydroxyprostaglandin E2 Analogues for Musculoskeletal Disorders - Drug Profile 212
teriparatide ZP Patch - Drug Profile 213
IBPB-008-IG - Drug Profile 215
KDM-1103 - Drug Profile 216
Osteoporosis - Recent Pipeline Updates 217
Osteoporosis - Dormant Projects 236
Osteoporosis - Discontinued Products 240
Osteoporosis - Product Development Milestones 241
Featured News & Press Releases 241
Appendix 248
Methodology 248
Coverage 248
Secondary Research 248
Primary Research 248
Expert Panel Validation 248
Contact Us 249
Disclaimer 249
List of Tables
Number of Products under Development for Osteoporosis, H1 2014 18
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 21
Number of Products under Development by Companies, H1 2014 (Contd..1) 22
Number of Products under Development by Companies, H1 2014 (Contd..2) 23
Number of Products under Development by Companies, H1 2014 (Contd..3) 24
Number of Products under Development by Companies, H1 2014 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Development, H1 2014 30
Comparative Analysis by Unknown Stage Development, H1 2014 31
Products under Development by Companies, H1 2014 32
Products under Development by Companies, H1 2014 (Contd..1) 33
Products under Development by Companies, H1 2014 (Contd..2) 34
Products under Development by Companies, H1 2014 (Contd..3) 35
Products under Development by Companies, H1 2014 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2014 37
Osteoporosis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 38
Osteoporosis - Pipeline by Amgen Inc., H1 2014 39
Osteoporosis - Pipeline by Eli Lilly and Company, H1 2014 40
Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 41
Osteoporosis - Pipeline by Merck & Co., Inc., H1 2014 42
Osteoporosis - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 43
Osteoporosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2014 44
Osteoporosis - Pipeline by CardioVascular BioTherapeutics, Inc., H1 2014 45
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2014 46
Osteoporosis - Pipeline by Novartis AG, H1 2014 47
Osteoporosis - Pipeline by Astellas Pharma Inc., H1 2014 48
Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 49
Osteoporosis - Pipeline by Pfizer Inc., H1 2014 50
Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 51
Osteoporosis - Pipeline by Azelon Pharmaceuticals Inc., H1 2014 52
Osteoporosis - Pipeline by Biodel Inc., H1 2014 53
Osteoporosis - Pipeline by Zosano Pharma, Inc., H1 2014 54
Osteoporosis - Pipeline by Bone Medical Limited, H1 2014 55
Osteoporosis - Pipeline by FAES Farma SA, H1 2014 56
Osteoporosis - Pipeline by Enzo Biochem, Inc., H1 2014 57
Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2014 58
Osteoporosis - Pipeline by Lupin Limited, H1 2014 59
Osteoporosis - Pipeline by Medivir AB, H1 2014 60
Osteoporosis - Pipeline by Calzada Limited, H1 2014 61
Osteoporosis - Pipeline by NeoStem, Inc., H1 2014 62
Osteoporosis - Pipeline by Dongwha Pharm Co., Ltd., H1 2014 63
Osteoporosis - Pipeline by PhytoHealth Corporation, H1 2014 64
Osteoporosis - Pipeline by Galapagos NV, H1 2014 65
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H1 2014 66
Osteoporosis - Pipeline by Oscotec Inc., H1 2014 67
Osteoporosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2014 68
Osteoporosis - Pipeline by Merrion Pharmaceuticals Plc, H1 2014 69
Osteoporosis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2014 70
Osteoporosis - Pipeline by Ventria Bioscience, H1 2014 71
Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H1 2014 72
Osteoporosis - Pipeline by Alkem Laboratories Ltd., H1 2014 73
Osteoporosis - Pipeline by Amura Holdings Ltd., H1 2014 74
Osteoporosis - Pipeline by Affectis Pharmaceuticals AG, H1 2014 75
Osteoporosis - Pipeline by IMMD Inc., H1 2014 76
Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H1 2014 77
Osteoporosis - Pipeline by Kedem Pharmaceuticals Inc., H1 2014 78
Osteoporosis - Pipeline by Asahi Kasei Pharma Corp., H1 2014 79
Osteoporosis - Pipeline by Pantarhei Bioscience BV, H1 2014 80
Osteoporosis - Pipeline by Zealand Pharma A/S, H1 2014 81
Osteoporosis - Pipeline by Siena Biotech S.p.A., H1 2014 82
Osteoporosis - Pipeline by Radius Health, Inc., H1 2014 83
Osteoporosis - Pipeline by Ensoltek Co., Ltd., H1 2014 84
Osteoporosis - Pipeline by Pradama, Inc., H1 2014 85
Osteoporosis - Pipeline by B&C Biopharm, H1 2014 86
Osteoporosis - Pipeline by TSRL, Inc., H1 2014 87
Osteoporosis - Pipeline by Pfenex Inc., H1 2014 88
Osteoporosis - Pipeline by Ausio Pharmaceuticals, LLC, H1 2014 89
Osteoporosis - Pipeline by Shenogen Pharma Group Ltd., H1 2014 90
Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2014 91
Osteoporosis - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 92
Osteoporosis - Pipeline by Bone Therapeutics SA , H1 2014 93
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2014 94
Osteoporosis - Pipeline by Centre de Regulacio Genomica, H1 2014 95
Osteoporosis - Pipeline by Covigilance sro, H1 2014 96
Osteoporosis - Pipeline by Amgen Astellas BioPharma K.K., H1 2014 97
Assessment by Monotherapy Products, H1 2014 98
Assessment by Combination Products, H1 2014 99
Number of Products by Stage and Target, H1 2014 102
Number of Products by Stage and Mechanism of Action, H1 2014 106
Number of Products by Stage and Route of Administration, H1 2014 109
Number of Products by Stage and Molecule Type, H1 2014 112
Osteoporosis Therapeutics - Recent Pipeline Updates, H1 2014 224
Osteoporosis - Dormant Projects, H1 2014 243
Osteoporosis - Dormant Projects (Contd..1), H1 2014 244
Osteoporosis - Dormant Projects (Contd..2), H1 2014 245
Osteoporosis - Dormant Projects (Contd..3), H1 2014 246
Osteoporosis - Discontinued Products, H1 2014 247
List of Figures
Number of Products under Development for Osteoporosis, H1 2014 18
Number of Products under Development for Osteoporosis - Comparative Analysis, H1 2014 19
Number of Products under Development by Companies, H1 2014 20
Number of Products under Investigation by Universities/Institutes, H1 2014 26
Comparative Analysis by Late Stage Development, H1 2014 28
Comparative Analysis by Clinical Stage Development, H1 2014 29
Comparative Analysis by Early Stage Products, H1 2014 30
Assessment by Monotherapy Products, H1 2014 98
Number of Products by Top 10 Target, H1 2014 100
Number of Products by Stage and Top 10 Target, H1 2014 101
Number of Products by Top 10 Mechanism of Action, H1 2014 104
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 105
Number of Products by Top 10 Route of Administration, H1 2014 108
Number of Products by Stage and Top 10 Route of Administration, H1 2014 109
Number of Products by Top 10 Molecule Type, H1 2014 110
Number of Products by Stage and Top 10 Molecule Type, H1 2014 111
